Table 4.
Patient preferences for pharmacogenomic testing: overall study sample (n = 128).
| Pharmacogenomic test attributes and levels | Preference weight | Standard error | Odds ratio (95% CI) | p-value |
|---|---|---|---|---|
| Identify best medication/dose | ||||
| Likely | Reference | |||
| Definitely | 0.74 | 0.07 | 2.09 (1.83; 2.39) | <0.001 |
| Identify/prevent side effects | ||||
| Likely | Reference | |||
| Definitely | 0.23 | 0.07 | 1.26 (1.09; 1.45) | 0.002 |
| Privacy/access | ||||
| Other third parties | Reference | |||
| Healthcare providers | 0.73 | 0.07 | 2.09 (1.82; 2.39) | <0.001 |
| Communication of the test results | ||||
| Either a pharmacist or a physician | Reference | |||
| A pharmacist | −0.12 | 0.09 | 0.88 (0.74; 1.06) | 0.18 |
| A physician | 0.11 | 0.10 | 1.12 (0.92; 1.36) | 0.25 |
| Involvement and advocacy for my treatment | ||||
| Likely | Reference | |||
| Definitely | 0.24 | 0.07 | 1.27 (1.11; 1.44) | <0.001 |
| Cost/insurance | ||||
| Fully covered by insurance | Reference | |||
| US$50, not covered | −0.43 | 0.10 | 0.65 (0.54; 0.78) | <0.001 |
| $500, not covered | −1.50 | 0.10 | 0.22 (0.19; 0.27) | <0.001 |
| Respondents (n) | 128 | Likelihood ratio χ2 (p-value) | 659.64 (<0.001) | |
| Observations (n) | 3072 | Pseudo R2 | 0.31 | |